roche glp-1 Baseline, Roche, Intellia, Eli Lilly: Readout Newsletter Mizuho's Jared Holz talks Roche

Several promising innovations are on the horizon, aimed at improving patient convenience, enhancing efficacy, reducing side effects, and tailoring therapy to individual needs

Consumers seeking berberine supplements may benefit from choosing products verified by independent organizations like USP or NSF International

Peptide YY and other satiety peptides demonstrate clear physiological roles, with early failures attributable to rapid exposure and intolerance rather than to a lack of efficacy, again favoring re-evaluation

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis

The connection isn't just a vague feeling

Tesamorelin Learn more about Tesamorelin here